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Abstract. Mild hyperhomocysteinaemia is associated 
with increased risk for vascular disease. We studied 
homocysteine export from human umbilical vein 
endothelial cells (HUVECs) by measuring total homo­
cysteine (tHcy) concentrations in the culture medium. 
Under standard culture conditions tHcy concentra­
tions in the HUVEC culture medium increased by 
constant amounts after 24, 48 and 72 h [mean = 2*5 
(SD ± 0-7) ¡in10IL “ 1 homocysteine every 24 h]. As the 
cells are the only source of homocysteine increase in 
the culture medium, we designate this as homocysteine 
export from HUVEC. Folic acid supplementation to 
the culture medium lowered the homocysteine export 
in a dose-dependent manner. Methyl-tetrahydrofolate 
(MeTHF) and folinic acid (a stable precursor of 
MeTHF) were in this respect about 10 times more 
effective than folic acid. A 50% reduction in the 
homocysteine export was seen with 10-30 nmol L 1 
MeTHF supplementation; reduction to almost zero 
was seen with 100-300 nmol L“ 1 MeTHF. Additions 
to the culture medium of the other vitamins involved 
in the homocysteine metabolism, such as vitamin Bi2, 
vitamin B6 and flavin adenine dinucleotide, did not 
show any effect on homocysteine export. Because 
homocysteine export reflects an imbalance in the 
homocysteine metabolism, our observations showed 
a susceptible dependency of this metabolism on folic 
acid in endothelial cells.
Keywords: Folic acid, human umbilical vein endothe­
lial cells, methionine/homocysteine metabolism.
Introduction
Severe hyperhomocysteinaemia (homocystinuria) is in 
most cases caused by an autosomal recessive inherited 
deficiency of cystathionine synthase (CS) or methyl- 
enetetrahydrofolate reductase (MTHFR) [1]. Clinic­
ally the most life-threatening complication of CS 
and MTHFR deficiency is severe arteriosclerosis or 
thrombosis [2,3]. Mild hyperhomocysteinaemia is
Correspondence: E. F. van der Molen, Department of Paedi­
atrics, University Hospital Nijmegen, PO Box 9101, 6500 HB 
Nijmegen, the Netherlands.
associated with the development of arteriosclerosis 
[4 6] and obstetric complications [7 9j. Mild hyper­
homocysteinaemia can theoretically be caused by 
reduced activities of CS, methionine synthase (MS) 
or MTHFR or by deficiencies of folic acid and 
vitamin Bp, Recently, a common mutation in the
I  w  v
MTHFR gene causing reduced enzymatic activity
has been described as one of the causes of mild 
hyperhomocysteinaemia [10] (Fig. D.
The treatment of hyperhomocysteinaemia (mild or 
severe) involves administration of pyridoxine, folic 
acid, vitamin B^ or hetaine [11|, In particular, admini­
stration of folic acid results in a strong decrease in 
plasma tHcy concentration in mild hyperhomoeystein- 
aemia and the combination of folic acid and pyridoxine 
normalizes mild hyperhomocysteinaemia in virtually 
all cases [12 14].
In vitro high levels of homocysteine can generate 
HiO-> and the vasotoxic properties of homocysteine 
through lipid peroxidation have been proposed [15]. 
However, in plasma from patients with severe hyper­
homocysteinaemia no increase in lipid peroxidation 
could be found [16,17], Several in vitro studies with 
endothelial cells have shown cell dysfunction when 
homocysteine is added to the medium. Lentz & Sadler 
[IK] showed that homocysteine reduced the thrombo­
modulin and von Willebrand factor excretion of 
HUVECs (human umbilical vein endothelial cells), 
Also, direct inactivation of protein C by homocysteine 
has been reported [19]. According to Nishinaga et ai 
[20] homocysteine reduces the expression of heparan 
sulphate on the cell membrane, and Hajjar [21] 
showed that the number of binding sites for tissue 
plasminogen activator (tPA) on the cell membrane 
may be reduced hv homocysteine. However, the above- 
mentioned studies used very high concentrations ol 
homocysteine in its reduced form (i,e. with free SH 
groups). This is extremely non-physiological because 
only 1% of homocysteine is present in blood in its 
reduced form. A dose of 10 mmol L 1 reduced homo­
cysteine in vitro is about 50 000 times higher than 
the amount of reduced homocysteine present in the
blood of patients with mild hyperhomocysteinaemia 
[22].
Little is known about the homocysteine metabolism
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Figure 1. Homocysteine metabolism. CS, cystathionine synthase; MTHFR, methylene tetrahydrofolate reductase; MS, 
methionine synthase.
in endothelial cells. Recent studies with lymphoma 
cells and fibroblasts described homocysteine export 
into the extracellular medium [23-25]. The homo­
cysteine export seemed to be dependent on cell pro­
liferation and additions to the culture medium of 
inhibitors of homocysteine metabolism. It was 
concluded that homocysteine export reflected an 
imbalance in homocysteine production and metabol- 
ism [11].
In the present paper homocysteine export was 
studied in human umbilical vein endothelial cells 
(HUVECs), including the effects of additions to the 
culture medium of vitamins involved in homocysteine 
metabolism.
Materials and methods
Cell culture
Endothelial cells from the human umbilical vein 
(HUVEC) were obtained from umbilical cords of 
healthy fetuses from uncomplicated pregnancies and 
deliveries of healthy mothers (non-smoking and with­
out medication). The cord was collected in buffer 
solution [4 mmol KC1, 140 mmol L-1 NaCl,
10 mmol L“ 1 HEPES, llm m o lL  1 D-glucose H20
(Merck, Germany), 105IU of penicillin and 105IU 
of streptomycin (Boeringer Mannheim, Germany) 
with pH 7-3.]
Within 24 h after cord collection endothelial cells 
were isolated by collagenase (Worthington, NJ, 
USA) treatment according to the procedure of 
JafTe et aL [26]. The endothelial cells were seeded 
in two wells of a six-well plate, 10 cm2 each (all 
tissue culture plastics used were from Costar, Cam­
bridge, MA, USA) coated with human cryoprecipitate 
(local bloodbank) and cultured in M l99 (Flow 
laboratories, Irving, UK) supplemented with 20 mmol 
L“ 1 Hepes (Merck, Germany), 10% human serum 
(local blood bank), 10% newborn calf serum (Gibco, 
Grand Island, NY, USA), 1% 200 mmol L/ " 1 L-gluta- 
mine (Flow ICN, USA), 5IUmL~l heparin (stock 
from our own pharmacy) and 150/^gmL“ 1 crude 
preparation of endothelial cell growth factor (Macaig 
el aL [27]) and incubated in 5% C02 and 95% air at 
37 °C, When cells reached confluence, they were 
detached by trypsin/EDTA sodium salt (Flow ICN, 
USA) (50 mg/25 mg) diluted in 100 mL of a solution of 
136-9 mmol L_1 NaCl, 5*4 mmol L "'1 KC1, 4-2 mmol 
L_INaHC03 , 5mmolL“ 1 D-glucose and 0*002% 
phenol red and seeded in the completely coated six- 
well plate (split ratio of 1:3). The medium was
(O 1996 Blackwell Science Ltd, European Journal of Clinical Investigation, 26, 304-309
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renewed every 2 or 3 days. All HUVEC experiments 
were performed with 3-day confluent cells from the 
second passage in six-well plates. The standard culture 
medium was removed and the test medium was 
applied, then, after incubations of 24, 48 or 72 h, the 
test medium was collected in separate ampoules and 
stored at —20°C for further analyses. After removal of 
the test medium the cells were trypsinized, counted by 
using the counter chamber (haemocytometer) and 
checked for viability with trypan blue. All experi­
ments were performed with at least three different 
HUVEC lines.
Homocysteine analysis
Total homocysteine (tHcy) concentrations were 
measured by an automated high-performance liquid 
chromatography (HPLC) method with reverse-phase 
separation and fluorescent detection (Gilson 232-401 
sample processor, Spectra Physics 8800 solvent delivery 
system and Spectra Physics LC 304 fluorimeter) 
essentially according to Fiskerstrand et aL [28] with 
some modifications (te Poele-Pothoff et aL [29]) the 
detection limit was 0*5 ¿¿mol L "1. The intra- and inter 
run variation coefficient was <5%. The tHcy analysis 
involved reduction of all disulphide bounds by sodium 
borohydride (Sigma, USA). After derivatization by 
monobromobimane (Sigma) the homocysteine- 
monobromobimane complex was separated by using 
reverse-phase HPLC.
In a small experiment, reduced homocysteine (with 
free SH groups) was added to the culture medium, the 
amount of reduced homocysteine in the culture medium 
was measured by binding free SH groups with DTNB 
[5,5'-dithiobis-(-nitrobenzoate) or Ellmans’s reagent]. 
The solution consisted of 0* 1 mmol L~1 DTNB, 0-1 mol 
L~! Tris, 0*3mmolL"1 acetyl CoA and 0*5mmol L~1 
oxaloacetate and absorption was measured at 412 nm 
[30].
Vitamin!methionine analysis
Vitamin Bl2 and total folic acid concentrations in 
medium and serum were measured simultaneously 
with Dualcount (solid-phase boil) SPB radioassay 
(Diagnostic Products Corporation, Los Angeles, CA, 
USA) as described previously [31]. According to the 
manufacturer (Flow Laboratories, Irving, UK), M l99 
contained 22*7 nmolL~l (0*01 mgL~!) folic acid. The 
total folic acid concentration in serum varied from 
16*1 to 31-6 nmol L-1, therefore the concentration of 
total folic acid in the standard culture medium could 
be calculated to be 21-4-24*5 nmol L”1. Measure­
ments of the total folic acid concentration in the 
culture medium showed a concentration of 26 nmol 
L“1. Methionine concentrations were determined 
using ion-exchange chromatography on an amino 
acid analyser (Biotronik LC 6001) according to the 
manufacturer’s instructions.
Added chemicals
Folic acid, 5-methyltetrahydrofolate (MeTHF), pyri- 
doxakvphosphate (PLP), methylcobalamin (Me- 
cobalamin), flavin adenine dinucleotide (FAD) and 
L-homocysteine thiolacton were obtained from Sigma. 
Hydroxocobalamin and folinic acid (leucovorin) were 
obtained from Byk Nederland,
Stock solution (for direct use) of 0*3moiL 1 l- 
homoeysteine in its reduced form (with free SH 
groups) was obtained by incubation of L-honio-
cysteine thiolacton in 20(5/¿L of NaOH (5molL “1) 
at 40"C for 5min and thereafter neutralized with 
400/¿L of phosphate buffer pH 7*8 (()• I mol L ') and 
400 /¿L of HC1 (2*5 mol L •). Reduced pure r.-homo- 
cysteine is not commercially available.
Results
Homocysteine concentrations in culture medium
*
The mean concentration of tHcy in fresh culture 
medium before incubation of 23 different experi­
ments was 3‘4/anolL 1 (range 3-0 4*3) and origi­
nated from the serum.
Addition of freshly prepared reduced homocysteine 
(i.e. with a free SH group) to the culture medium 
resulted in a rapid decline in the concentration of 
reduced homocysteine. The half-life of reduced homo­
cysteine in culture medium was 2 3 Ik  Free SH groups 
are reactive and will be rapidly oxidized to disul­
phides, In human plasma only 1% of the total 
amount of homocysteine is present in the reduced 
form [11]. The half-life of reduced homocysteine was 
the same when no HUVECs or coating of human 
cryopreeipitatc was present and therefore the decline 
of reduced homocysteine was independent of cell 
exposure or coating. Incubation with 50 100/¿mol 
L 1 t.-homoeysteine for 24 h showed no efleet on 
HUVECs (visually and cell viability) when compared 
with cells incubated in standard medium (data not 
shown).
Homocysteine export, methionine and folic acid 
concentrations in endothelial cell culture medium
When cells were in the second passage and at least 3 
days in monolayer under standard culture conditions, 
the cells exported a fairly constant amount of homo­
cysteine in the culture medium. Experiments with six 
different HUVEC lines showed similar results, with a 
mean homocysteine export after 24 h of 2*4 (SD ± 0*6) 
//molL between 24 and 48 h of 2-7 (SDdtO-9) 
/¿molL 1 and between 48 and 72 h of 2*3 (SD±0-7) 
//.mol L 1 (Fig. 2),
The concentration of methionine decreased from 80
to 69//mol L 1 in 72 h and the concentration of folic 
acid from 26 to 23 nmol L 1 in 72 h and the concen­
tration of vitamin BP from ISO to IftOpmolL 1 in
72 h.
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Figure 2. Mean (±SD) of total homocysteinc concentrations in the 
HUVEC culture medium after incubation of 0, 24,48 and 72 h of six 
different HUVEC lines under standard culture conditions.
Homocysteine, export and effects of vitamin addition
Folic acid. Supplementing the standard culture 
medium of HUVECs with folic acid reduced homo­
cysteine export in a dose-dependent manner. Addition 
of 300 nmol L~"J folic acid reduced homocysteine 
export by about 50%. When 3-10/xmolL“1 folic 
acid was added, homocysteine export was almost 
zero. Experiments with two other cell lines showed 
similar results (Table 1). Addition of folic acid did not 
affect cell number or viability.
Table 1. Homocysteine concentrations in HUVEC culture medium 
after incubation minus the homocysteine concentration already
present in the culture medium before incubation
tl-lcy /¿molL" 1 (±SD)
24 li 48 h 72 h
Folic acid (nmol L”1)
0 2-0 (d= 0-4) 5*2 (±1-1) 7*9 (±0*3)
100 1-9 (±0-4) 4*0 (±0*2) 6*9 (±0 *2 )
300 1*3 (±0-3) 3*1 (db0’3) 4*8 (±0*9)
1000 0-7 (±0*7) 1*4 (±0*2) 2*8 (±1*3)
3000 0-3 (±0-6) 0*2 (±0 *1) 1*7 (±2*1)
10000 0-1 (±0 -6 ) 0-1 (±0 *2 ) 1*1 (±1-7)
MeTHF (nmol L r1)
0 1 ‘6 (±0 '6 ) 3*5 (±1*1) 6*1 (±1*6)
10 0-8 (±0 *8 ) 2*7 (±1*1) 4*0 (±4*0)
30 0-6 (±0-5) 1*9 (±1*3) 3-0 (± H )
100 0*3 (±0*5) 0*9 (±0*9) 2*1 (±1*0)
1000 0-3 (±0*7) 0*1 (±0 -6 ) 1*2 (±1*1)
Folinic acid (nmol L~l)
0 2*1 (±1-3) 4-5 (±1*7) 6*6 (±2 *1)
10 1*2 (±0*9) 1*8 (± 1*1) 2*9 (±1*4)
30 0*9 (±1-0) 1*8 (± 1*0 ) 2*1 (±1*5)
100 0*4 (±0*8) 0-8 (±0*5) 1*7 (±1*8)
1000 0*2 (±0*4) 0-6 (±0 *8) 0*7 (±0*9)
Incubation times were 24, 48 and 72 h. The culture medium was 
supplemented with various concentrations of folic acid (0, 0*i, 0-3, 
1,3 and 10/rniolL"1), MeTHF (0, 10, 30, 100, 1000 nmol L“1) and
folinic acid (0 , 10, 30, 100, 1000 nmol L“1)*
MeTHF and folinic acid. Medium M199 contained 
only folic acid (i.e. its oxidized form). The serum also 
contributed to the folic acid level of the standard 
culture medium (see Materials and methods). Because 
MeTHF is the main circulating form of folic acid in 
the body, we considered in our calculations the 
amount of folic acid in serum as MeTHF. There­
fore, the baseline concentration of MeTHF in the 
standard culture medium was considered to be 
4*7 nmol L”1. Addition of various concentrations of 
MeTHF or folinic acid (the more stable precursor of 
MeTHF) to the culture medium reduced homo­
cysteine export in a dose-dependent manner, A typi­
cal presentation of this dose dependency is shown in 
Fig. 3. The concentrations of MeTHF or folinic acid 
were about 10 times lower than that of folic acid 
required to observe similar homocysteine export 
reduction (Table 1), Homocysteine export was reduced 
by 50% by addition of 10-30 nmol L-1 MeTHF or 
folinic acid, and addition of 100-300 nmol L~l 
resulted in almost zero homocysteine export (Table 
1). Experiments with two other cell lines showed 
similar results, Folinic acid seems to be more effective 
in reducing the homocysteine export than MeTHF, 
although MeTHF is the direct substrate in the remethy- 
lation of homocysteine in methionine.
Hydroxocobalamin/Me-cobalamin, PLP and FAD. 
Me-cobalamin (active form of vitamin BI2) is a co- 
factor of methionine synthase in the remethylation of 
homocysteine to methionine. Medium M l99 con­
tained no vitamin B12. The concentration of vitamin 
Bl2 in the culture medium was (due to its presence in 
serum) 180 pmol L”"1. Addition of extra vitamin B12 to 
the culture medium either in the form of hydroxo­
cobalamin or Me-cobalamine had no effect on the 
homocysteine export (Table 2).
PLP (active form of vitamin B6) is the co-factor of 
cystathionine /3-synthase (CS), which catalyses the
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Figure 3. Homocysteine concentrations in HUVEC culture medium 
after incubations of 0, 24, 48 and 72 h with MeTHF added to the 
culture medium in the following concentrations: (■), 0 (control); 
(□), 10 nmol L“1; (•), 30 nmol I / “1; (O), 100 nmol L"4; (A), 
I ¿¿mol L-1.
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Table 2. Homocysteine concentrations in 
HUVEC culture medium after incubation 
minus the hoinocysteinc concentration 
already present in the culture medium
before incubation
tHcy (/¿molL l)
24 h 48 h 72 h
Me-cobalamin (ninol L~')
0 1*6 3*3 5*1
I 1*7 2-7 6-0
102 1-6 3*1 5-5
104 2*0 4*3 6*6
PLP (/¿mol L-')
0 1*6 3-3 5*1
10 1*8 3-5 5*6
100 1-7 3-5 5*1
FAD (nmol L-1)
0 2-0 4*9 6*7
120 2-3 4*9 6-7
300 2-1 6*4 7-7
750 2-4 4*9 7-7
Incubation times were 24, 48 and 72 h. 
The culture medium was supplemented with 
various concentrations of Me-cobalamin
(0, I, 10-, 104 nmolL"1), PLP (0, 10, 
100/¿mo! L~') and FAD (0, 120, 300, 
7 50 nmol L“1).
conversion of homocysteine in cystathionine. Stan­
dard culture medium contained 2*2 jimol L ~1 (0*05 mg 
L“1) vitamin B6. Addition of PLP did not reduce the 
homocysteine export (Table 2).
FAD is a co-factor of MTHFR in the formation 
of MeTHF from methylene-THF. Standard culture 
medium contained 0-01 m gL“1 riboflavin (stable pre­
cursor of FAD), and the addition of FAD to the 
culture medium did not affect homocysteine export 
(Table 2). In all experiments the cell number and the 
cell viability were not influenced by the additions of 
these vitamins.
Discussion
HUVECs exported homocysteine at a virtually con­
stant rate over 72 h under standard culture conditions 
(Fig. 2). This effect was highly reproducible in six 
different HUVEC lines. The cell number and cell 
viability remained unchanged and the concentrations 
in the culture medium of methionine, vitamin B12 and 
total folic acid decreased only slightly over 72 h.
Addition of folic acid to the medium reduced 
homocysteine export in a dose-dependent manner. 
MeTHF is the main circulating form of folic acid in 
blood and is a direct substrate in homocysteine 
remethylation. MeTHF also reduced homocysteine 
export in a dose-dependent manner, at a 10 times 
lower concentration than folic acid (Table 1). Folinic 
acid, a more stable one-carbon THF precursor of 
MeTHF, showed similar results. In addition, folinic
acid had a greater tendency to reduce homocysteine 
export than MeTHF, probably because of its higher 
stability.
In our hospital, normal folate levels in human 
plasma are considered to be between 7 and 30 nmol 
L l . Extrapolating to the in vitro situation this means 
that endothelial cells are exporting a fair amount of 
homocysteine in the presence of normal folate levels. 
Even after addition of 10 30 nmol L 1 MeTHF, the 
main form of folate in blood, a homocysteine export 
of 50% of the initial value was still observed.
Additions of other vitamins involved in homo­
cysteine metabolism, such as Me-cobalamin, PLP 
and FAD, had no effect on homocysteine export 
[32], An explanation is that these compounds are co- 
factors of the enzymes of homocysteine metabolism, 
whereas MeTHF is a substrate of homocysteine 
remethylation.
Refsum et aL [23] and Christensen et aL [24,25] 
studied homocysteine export in murine lymphoma 
cells, rat liver cells and in human fibroblasts, but not 
in human endothelial cells. In the celt homocysteine is 
either converted to cysteine or salvaged to methionine 
through remethylation or exported from the intracel­
lular compartment into the extracellular medium. 
Ueland et aL [11] concluded that homocysteine 
export reflects an imbalance between homocysteine 
production and metabolism. In this study with 
HUVECs, the imbalance in homocysteine metabol-1 * 
ism, as reflected by the high homocysteine export, 
disappeared after addition of folates to the medium.
In the human body the concentration of homocyst­
eine in plasma is probably dependent on cellular 
homocysteine export and on the capacity for homo­
cysteine degradation, mainly in liver and kidney [33]. 
Dysfunction of each of these systems can theoretically 
cause hyperhomocysteinaemia [l,2|. The observed 
imbalance in the homocysteine metabolism in cul­
tured endothelial cells may reflect the in vitro situ-
w
ation but, on the other hand, it mav reflect a natural 
feature of endothelial cells that can contribute to the 
vulnerability of endothelial cells to mild hyperhomo­
cysteinaemia, C ertain conditions are likely to enhance 
homocysteine export, such as disruption of the endo­
thelial cell layer (resulting in repair, thus enhanced cell 
proliferation) or of the composition of the extracel­
lular fluid (shortage of vitamins, higher levels of 
methionine or administration of certain drugs such 
as methotrexate).
Homocysteine-lowering therapy in patients with 
severe hyperhomocysteinaemia has proved to be 
clinically beneficial [3]. In mild hyperhomocystein­
aemia, such clinical effects remain to be determined. 
Folic acid regiments are very effective in lowering 
plasma homocysteine levels in vivo [12,13]. In this 
study, folic acid proved to he very effective in main­
taining low homocysteine levels in the culture 
medium, probably as a result of the restored balance 
of the homocysteine metabolism in the cultured 
endothelial cells.
in 1996 Blackwcll Science Ltd, European Journal of ( ‘Itnnal 26, 304 309
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